TENX News and Press, Tenax Therapeutics Inc.

2024-05-14 13:53:46 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Tenax Therapeutics (NASDAQ: TENX ) just reported results for the first quarter of 2024. Tenax Therapeutics reported earnings per share of -$3.12. This was below the analys...

2024-05-14 10:42:08 ET More on Tenax Therapeutics Seeking Alpha’s Quant Rating on Tenax Therapeutics Historical earnings data for Tenax Therapeutics Financial information for Tenax Therapeutics Read the full article on Seeking Alpha For further...

Currently Enrolling Patients in Phase 3 LEVEL Study with 24 Investigative Sites Initiated Secured Global Development and Commercial Rights to Levosimendan for Treatment of PH-HFpEF Expanded Intellectual Property Estate for Levosimendan with Issuance of New U.S. Patent ...

Broadens IP protection for oral (TNX-103), IV, and subcutaneous use of levosimendan, and its active metabolites (OR1896 and OR1855), in PH-HFpEF Provides U.S. intellectual property (IP) protection until December 2040, and may qualify for additional U.S. patent term extension (PTE) beyond ...

2024-04-18 07:27:32 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Pre-market stock movers are worth checking out as we dive into all of the biggest news sending shares higher and lower on Thursday morning! Moving stocks this morning are earnings reports, ...

Panel of renowned cardiologists, all globally recognized experts in heart failure, will discuss the unmet medical need in pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF) and the potential role for levosimendan in treating this prevalent, fatal disease ...

2024-03-28 08:44:11 ET More on Tenax Therapeutics Tenax surges after patent win for heart failure therapy Seeking Alpha’s Quant Rating on Tenax Therapeutics Historical earnings data for Tenax Therapeutics Financial information for Tenax Therapeutics ...

First Patient Enrolled in Phase 3 LEVEL Trial Evaluating TNX-103 (oral levosimendan) for the Treatment of Pulmonary Hypertension from Heart Failure with Preserved Ejection Fraction (PH-HFpEF) Expansion of U.S. Intellectual Property Covering the Use of Levosimendan for the Treatment of PH-...

Community Bancorp Inc Vermont (CMTV) is expected to report for Q4 2023 CISO Global, Inc (CISO) is expected to report for Q4 2023 TCTM Kids IT Education Inc. (TCTM) is expected to report for quarter end 2023-12-31 Generation Income Properties Inc. (GIPR) is expected to report for quart...

Lendway Inc. (LDWY) is expected to report for quarter end 2023-12-31 Hongchang International Co Ltd Com (New) (HCIL) is expected to report for Q4 2023 BioStem Technologies Inc (BSEM) is expected to report $0.47 for Q4 2023 Nicox SA (NICXF) is expected to report $-0.07 for Q4 2023 ...